Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing biopharmaceutical research companies, supports the FDA's initiative to revise and consolidate the SUPAC guidances to reflect modern manufacturing practices. They argue for a risk-based approach that incorporates prior knowledge, aligns with international ICH guidelines, and accommodates emerging technologies like continuous manufacturing.